As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

"The global regenerative medicine markets comprises of many key market players competing for markets shares like Novartis AG ...

New Omdia analysis has revealed the MENA cinema market is poised for substantial revenue growth, projected to increase from $900 million in 2024 to $1.5 billion by 2029. The Kingdom of Saudi Arabia is ...

Elanco Animal Health Incorporated today announced the appointment of Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma brings extensive global leadership experience in ...

Mumbai: Global pharma major Lupin Limited has announced ... 200 mg/25 mg, of Gilead Sciences, Inc. Lupin Limited is a global ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.

Headquartered in Foster City, California, Gilead Sciences, Inc. (GILD) is a prominent biopharmaceutical company with a market cap of $114.2 billion. Gilead specializes in developing and ...

Revenue: US$7.55b (up 7.0% from 3Q 2023). Net income: US$1.25b (down 43% from 3Q 2023). Profit margin: 17% (down from 31% in 3Q 2023). EPS: US$1.01 (down from US$1.75 in 3Q 2023). Revenue exceeded ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.